Albany Molecular Research Inc.'s $210 Million Senior Secured First-Lien Term Loan Due 2024 Rated 'B-' (Recovery: '3') - S&P Global Ratings’ Credit Research

Albany Molecular Research Inc.'s $210 Million Senior Secured First-Lien Term Loan Due 2024 Rated 'B-' (Recovery: '3')

Albany Molecular Research Inc.'s $210 Million Senior Secured First-Lien Term Loan Due 2024 Rated 'B-' (Recovery: '3') - S&P Global Ratings’ Credit Research
Albany Molecular Research Inc.'s $210 Million Senior Secured First-Lien Term Loan Due 2024 Rated 'B-' (Recovery: '3')
Published Oct 19, 2020
4 pages (1722 words) — Published Oct 19, 2020
Price US$ 150.00  |  Buy this Report Now

About This Report

  
Abstract:

NEW YORK (S&P Global Ratings) Oct. 19, 2020--S&P Global Ratings today assigned its 'B-' issue-level rating and '3' recovery rating to Albany, N.Y.-based contract development and manufacturing organization (CDMO) Albany Molecular Research Inc.'s (AMRI) proposed $210 million senior secured first-lien term loan due 2024. The '3' recovery rating indicates our expectation for average (50%-70%; rounded estimate: 50%) recovery in the event of a payment default. We expect the company to use the proceeds from this term loan to redeem the $205 million outstanding on its second-lien term loan maturing in August 2025. We view the transaction as effectively leverage neutral. Our 'B-' long-term issuer credit rating and stable outlook on AMRI reflect its modest scale (less than $1 billion in

  
Brief Excerpt:

...- Our simulated default scenario contemplates a default occurring in 2022, potentially stemming from a regulatory suspension of its manufacturing operations at one or more facilities. - We believe AMRI would likely reorganize in the event of default and value the company on a going-concern basis using a 6x multiple of our projected default-level EBITDA. This multiple is similar to the multiples we use for other CDMOs based on their scientific expertise and specialized facilities. - The secured credit facilities benefit from a downstream guarantee from UIC Parent Co., an upstream guarantee from the company's wholly owned U.S. restricted subsidiaries, and a pledge of 65% of AMRI's equity interests in its foreign subsidiaries. AMRI's U.S. operations, which provide a secured guarantee to the facilities, contribute approximately 50% of its revenue. Its foreign operations, which are nonguarantors, contribute the remaining 50% of its revenue. Simulated default assumptions - Simulated year of default:...

  
Report Type:

Ratings Action

Issuer
GICS
Life Sciences Tools & Services (35203010)
Sector
Global Issuers
Country
Region
Format:
PDF Adobe Acrobat
Buy Now

S&P Global Ratings’ Credit Research—S&P Global Ratings’ credit research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P Global Ratings also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.

About the Author


Cite this Report

  
MLA:
S&P Global Ratings’ Credit Research. "Albany Molecular Research Inc.'s $210 Million Senior Secured First-Lien Term Loan Due 2024 Rated 'B-' (Recovery: '3')" Oct 19, 2020. Alacra Store. May 04, 2025. <http://www.alacrastore.com/s-and-p-credit-research/Albany-Molecular-Research-Inc-s-210-Million-Senior-Secured-First-Lien-Term-Loan-Due-2024-Rated-B-Recovery-3-2538170>
  
APA:
S&P Global Ratings’ Credit Research. (). Albany Molecular Research Inc.'s $210 Million Senior Secured First-Lien Term Loan Due 2024 Rated 'B-' (Recovery: '3') Oct 19, 2020. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/s-and-p-credit-research/Albany-Molecular-Research-Inc-s-210-Million-Senior-Secured-First-Lien-Term-Loan-Due-2024-Rated-B-Recovery-3-2538170>
  
US$ 150.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.